Current role and safety profile of aromatase inhibitors in early breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1253-1263

  Tomao, Federica ^a   Spinelli, GianPaolo ^a   Vici, Patrizia ^b   Pisanelli, Giovanni Codacci ^a   Cascialli, GianLuca ^a   Frati, Luigi ^a   Panici, PierLuigi Benedetti ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adjuvant therapy; aromatase inhibitors; breast cancer; estrogens; tamoxifen

Indexed keywords

25 HYDROXYVITAMIN D; AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; GABAPENTIN; GONADORELIN DERIVATIVE; LETROZOLE; PLACEBO; PRASTERONE; PROGESTERONE RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; ZOLEDRONIC ACID;

AMENORRHEA; ANXIETY; ARTHRALGIA; ARTHROPATHY; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL RETINA VEIN THROMBOSIS; COGNITIVE DEFECT; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; EARLY CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; ESTROGEN SYNTHESIS; FATIGUE; FRACTURE; GENITOURINARY ATROPHY; GYNECOLOGIC DISEASE; HEART FAILURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; LEARNING DISORDER; LIBIDO DISORDER; LIPID METABOLISM; LUNG EMBOLISM; MEMORY DISORDER; MONOTHERAPY; MOOD CHANGE; MUSCULOSKELETAL DISEASE; MYALGIA; NIGHT SWEAT; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; POSTMENOPAUSE; REVIEW; SIDE EFFECT; SUPERFICIAL THROMBOPHLEBITIS; THROMBOEMBOLISM; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT DISEASE; UTERINE CERVIX TUMOR; UTERUS FIBROMA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS;

EID: 80052312353     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.96     Document Type: Review

References (62)

1. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979 (2003).
2. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr. Relat. Cancer 17(4), R245-R262 (2010).
3. Lin SX, Chen J, Mazumdar M et al. Molecular therapy of breast cancer: Progress and future directions. Nat. Rev. Endocrinol. 6(9), 485-493 (2010).
4. Mansell J, Monypenny IJ, Skene AI et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res. Treat 100(Suppl. 1) 2006) (Abstract 2091 100(Suppl. 1) (2006) (Abstract 2091).
5. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr. Relat. Cancer 11, 391-406 (2004).
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351, 1451-1467 (1998).
7. Lenning PE, GeislerJ. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. J. Steroid Biochem. Mol. Biol. 108(3-5), 19, 600-602 (2008).
8. Buzdar A, Chlebowski R, Cuzick J et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr. Med. Res. Opin. 22(8), 1575-1585 2006)
9. Baum M, Budzar AU, Cuzick J et al. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
10. Baum M, Buzdar A, Cuzick J et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802-1810 (2003).
11. Howell A, Cuzick J, Baum M et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005). Cornerstone article showing the superiority of the aromatase inhibitor (AI) anastrazole in early breast cancer.
12. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008).
13. Thurlimann B, Keshaviah A, Coates AS et al.; for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005). First study showing the superiority of the AI letrozole in terms of reduction of relapse at the metastatic site.
14. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: Update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007).
15. Mouridsen H, Giobbie-Hurder A, Mauriac L et al. BIG 1-98: A randomized doubleblind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptorpositive breast cancer. Proc. SABCS (2008) (Abstract 13).
16. Viale G, Regan MM, Dell'Orto P et al. Central Review of ER, PgR and HER2 in BIG 1-98 evaluating letrozole vs. letrozole followed by tamoxifen vs. tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. Proc. SABCS (2009) (Abstract 76).
17. Rea D, Hasenburg A, Seynaeve C et al. Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormonesensitive early breast cancer. Proc. SABCS (2009) (Abstract 11).
18. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 7, 991-996 (2010).
19. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 2004
20. Coombes RC, Kilburn LS, Snowdon CF et al. Intergroup exemestane study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup exemestane study): A randomised controlled trial. Lancet 369, 559-570 (2007).
21. Chia SK, Speers CH, Bryce CJ et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion negative early breast cancers without adjuvant systemic therapies. J. Clin. Oncol. 22, 1630-1637 (2004).
22. Peto R, Davies C; on behalf of the Collaboration. Adjuvant Tamoxifen, Longer Against Shorter: International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women: Preliminary results. Proc. SABCS (2007) (Abstract 48).
23. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
24. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262-1271 (2005).
25. Mamounas E, Jeong J-H, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): Intent-to-treat analysis of NSABP B-33. Breast Cancer Res. Treat 100(Suppl. 1), S22 (2006) (Abstract 49).
26. Forward DP, Cheung KL, Lackson L. Clinical and endocrine data for goserelin plus second line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 90, 590-594 (2004).
27. Gnant M., Mineritsch B, Schippinger W. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
28. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Miner. Res. 21, 1215-1223 (2006).
29. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J. Clin. Oncol. 24, 3629-3635 2006)
30. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months results of the ZO-FAST Study. Ann. Oncol. 21(11), 2188-2194 (2010).
31. Gnant M, Mlineritsch B, Luschin G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage brest cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9(9), 840-849 (2008).
32. Crew KD, Greenlee H, Capodice J et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J. Clin. Oncol. 25(25), 3877-3883 (2007). Innovative article showing clinical evidence of the risk of AI-related joint symptoms in the adjuvant therapy of early breast cancer.
33. Goss PE, Ingle JN, Martino S et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2009 (Abstract 13).
34. Looker AC, Dawson-Hughes B, Calvo MS et al. Serum 25-hydoxyvitamin D status of adolescents and adults in two seasonal subpopulations from BHANES III. Bone 30, 771-777 (2002).
35. Crew KD, Capodice JL, Greenlee H et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J. Clin. Oncol. 28(7), 1154-1160 (2010).
36. Bender CM, Sereika SM, Brufsky AM et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6), 995-998 (2007).
37. Phillips KA, Aldridge J, Ribi K et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 126(1), 221-226 (2010).
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472), 2005). Confirmation at 15 years of follow-up in randomized trials of the positive effects on survival of chemotherapy and hormonal therapy for early breast cancer.
39. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
40. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: Update of study BIG 1-98. J. Clin. Oncol. 25(5), 486-492 (2007). Update confirming the positive results of the BIG 1-98 study published in the New England Journal of Medicine in 2005.
41. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369(9561), 559-570 (2007).
42. Ganz PA, Desmond KA, Berlin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. J. Clin. Oncol. 2371-2380 1999)
43. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008).
44. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J. Clin. Oncol. 1, 25(19), 2664-70 (2007).
45. Fallowfield L, Bliss J, Porter L et al. Quality of life in the Intergroup Exemestane Study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J. Clin. Oncol. 24, 910-917 (2006).
46. Jones SE, Cantrell J, Vukelja S et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J. Clin. Oncol. 25(30), 4765-4771 2007)
47. Buzdar A, Howell A, Cuzick J et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Lancet Oncol. 7(8), 633-643 (2006).
48. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann. Oncol. 17(4), 584-587 (2006).
49. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6(1), 45-52 (2003).
50. Labrie F, Archer D, Bouchard C et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5), 923-931 (2009).
51. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351, 1451-1467 (1998).
52. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
53. The Breast International Group (BIG 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2006).
54. Van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 22, 377(9762), 321-331 (2011).
55. Bertelli G, Hall E, Ireland E et al.. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES) - a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann. Oncol. 21(3), 498-505 (2010).
56. Jakesz R, Jonat W, Mittlboeck M. Switching of postmenopausal women with endocrine- responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
57. Coombes RC, Hall E, Gibson LJ et al. The intergroup exemestane study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [published erratum appears in N. Engl. J. Med. 351, 2461 (2004).]
58. N. Engl. J. Med. 350, 1081-1092 (2004). Innovative clinical approach demonstrating that exemestane therapy after 2-3 years of tamoxifen therapy significantly improves disease-free survival compared with the standard 5 years of tamoxifen treatment.
59. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J. Clin. Oncol. 23, 5138-5147 2005)
60. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. Cancer Spec. 97, 1262-1271 (2005). Demonstrates that letrozole, after tamoxifen, improves both disease-free and distant disease-free survival but not overall survival, with the exclusion of node-positive patients.
61. Jakesz R. Extended adjuvant treatment with anastrozole: Results from the Austrian breast and colorectal cancer study group trial 6a (ABCSG-6a). ASCO annual meeting (2005) (Abstract 527).
62. Burdette-Radoux S, Muss HE. A question of duration: Do patients with early stage breast cancer need more than five years of adjuvant endocrine therapy? Clin. Breast Cancer 9(Suppl. 1), S37-S41 (2009).